A Landmark Alzheimer’s Drug Approval Would Likely Deepen Racial Inequities in Dementia Care

Other researchers are not convinced that these biomarkers vary by race, primarily because so little Alzheimer’s research has been conducted on Black and Latinx people. “We don’t know these differences exist and the reason we don’t know is we have an inequitable system,” said Jennifer Manly, a professor in the Columbia University neurology department who studies predictors of Alzheimer’s disease in Black and Hispanic populations. “Not only has research been occurring in clinics with mostly white people, the research is occurring on mostly well-educated and well-resourced white people.” [read more]
Source: STAT